Lentivirus-mediated transduction of PKR into CD34+ hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny

Journal of Interferon and Cytokine Research

Volumn 25, Issue 6, 2005, Pages 345-360

  Dimitrova, Dessislava I ^a   Yang, Xiaowei ^a   Reichenbach, Nancy L ^a   Karakasidis, Stephanos ^a   Sutton, Richard E ^b   Henderson, Earl E ^a   Rogers, Thomas J ^a   Suhadolnik, Robert J ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLASTICIDIN S; CD34 ANTIGEN; PHOSPHOTRANSFERASE; PROTEIN KINASE R; PROTEIN P68; PROTEIN P68 KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL VIABILITY; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; GENETIC TRANSDUCTION; HEMATOPOIETIC STEM CELL; HOST RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRIDIZATION; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETROVIRUS; T LYMPHOCYTE; TRANSGENE; VIRUS REPLICATION;

ANTIGENS, CD34; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELLS, CULTURED; EIF-2 KINASE; GENETIC VECTORS; HEMATOPOIETIC STEM CELLS; HIV INFECTIONS; HIV-1; HUMANS; T-LYMPHOCYTE SUBSETS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

EUKARYOTA; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; MAMMALIA;

EID: 21344457676     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2005.25.345     Document Type: Article

References (75)

1. DEVITA, V.T., HELLMAN, S., and ROSENBERG, S.A., editors. (1997). AIDS: Etiology, Diagnosis, Treatment and Prevention, 4th ed. Philadelphia: Lippincott-Raven.
2. PALELLA, F.J., DELANEY, K.M., MOORMAN, A.C., LOVELESS, M.O., FUHRER, J., SATTEN, G.A., ASCHMAN, D.J., and HOLMBERG, S.D. (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338, 853-860.
3. BLANKSON, J. N., PERSAUD, D., and SILICIANO, R.F. (2002). The challenge of viral reservoirs in HIV-1 infection. Annu. Rev. Med. 53, 557-593.
4. PERSAUD, D., ZHOU, Y., SILICIANO, J. M., and SILICIANO, R.F. (2003). Latency in human immunodeficiency virus type 1 infection: no easy answers. J. Virol. 77, 1659-1665.
5. VALENTIN, A., ROSATI, M., PATENAUDE, D.J., HATZAKIS, A., KOSTRIKIS, L.G., LAZANAS, M., WYKILL, K.M., YARCHOAN, R., and PAVLAKIS, G.N. (2002). Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 99, 7015-7020.
6. SAMUEL, C.E. (2001). Antiviral actions of interferons. Clin. Microbiol. Rev. 14, 778-809.
7. SEN, G.C. (2001). Viruses and interferons. Annu. Rev. Microbiol. 55, 255-281.
8. GOODBOURN, S., DIDOCK, L., and RANDALL, R.E. (2000). Interferons: cell signaling, immune modulation, antiviral responses and virus countermeasures. J. Gen. Virol. 81, 2341-2364.
9. CARTER, W.A., STRAYER, D.R., BRODSKY, I., LEWIN, M., PELLEGRINO, M.G., EINCK, L., HENRIQUES, H.F., SIMON, G.L., PARENTI, D.M., SCHEIB, R.G., SCHULOF, R.S., MONTEFIORI, D.C., ROBINSON, W.E., MITCHELL, W.M., VOLSKY, D.H., PAUL, D., PAXTON, H., MEYER, W.A., III, KARIKO, K., REICHENBACH, N., SUHADOLNIK, R.J., and GILLESPIE, D.H. (1987). Clinical, immunological and virological effects of Ampligen, a mismatched double-stranded RNA, in patients with AIDS or AIDS-related complex. Lancet 1, 1286-1292.
10. SKILLMAN, D.R., MALONE, J.L. DECKER, C.D., WAGNER, K.F., MAPOU, R.L. LIAO, M.J., TESTA, D., and MELTZER, M.S. (1996). Phase I trial of Interferon alpha-n3 in early-stage human immunodeficiency virus type 1 disease: evidence for drug safety, tolerance, and antiviral activity. J. Infect. Dis. 173, 1107-1114.
11. KOVACS, J.A., BECHTEL, C., DAVEY, R.T., Jr., FALLOON, J., POLIS, M.A., WALKER, R.E., METCALF, J.A., DAVEY, V., PISCITELLI, S.C., BASELER, M., DEWAR, R., SALZMAN, N.P., MASUR, H., and LANE, H.C. (1996). Combination therapy with didanosine and interferon-alpha in human immunodeficiency virus-infected patients: results of a phase I/II trial. J. Infect. Dis. 173, 840-848.
12. BEDNARIK, O.P., MOSCA, J.D., RAJ, N.B., and PITHA, P.M. (1989). Inhibition of human immunodeficiency virus (HIV) replication by HIV-transactivated α2-interferon. Proc. Natl. Acad. Sci. USA 86, 4958-4962.
13. SU, Y., POPIK, W., and PITHA, P.M. (1995). Inhibition of human immunodeficiency virus type 1 replication by a tat-activated, transduced interferon gene: targeted expression to human immunodeficiency virus type 1-infected cells. J. Virol. 69, 110-121.
14. RAGHEB, J.A., COUTURE, L., MULLEN, C., RIDGWAY, A., and MORGAN, R.A. (1999). Inhibition of human immunodeficiency virus type 1 by Tat/Rev regulated expression of cytosine deaminase, interferon α2, or diphtheria toxin compared with inhibition by transdominant. Rev. Hum. Gene Ther. 10, 103-112.
15. CORDELIER, P., CALAROTA, S.A., and STRAYER, D. S. (2002). Trans-activated interferon-alpha2 delivered to T cells by SV40 inhibits early stages in the HIV-1 replicative cycle. J. Hematother. Stem Cell Res. 11, 817-823.
16. CORDELIER, P., CALAROTA, S.A., POMERANTZ, R.J., XIAOSHAN, J., and STRAYER, D.S. (2003). Inhibition of HIV-1 in the central nervous system by IFN-α2 delivered by an SV40 vector. J. Interferon Cytokine Res. 23, 477-488.
17. BALTIMORE, D. (1988). Intracellular immunization. Nature 355, 7395-7396.
18. SCHRÖDER, H.C., SUHADOLNIK, R.J., PFLEIDERER, W., CHARUBALA, R., and MÜLLER, W.E. (1992). (2′-5′)Oligoadenylate and intracellular immunity against retrovirus infection. Int. J. Biochem. 24, 55-63.
19. ADELSON, M.E., MARTINAND-MARI, C., IACONO, K.T., MUTO, N.F., and SUHADOLNIK, R.J. (1999). Intracellular immunization: inhibition of human immunodeficiency virus (HIV-1) replication in SupT1 cells transduced with an HIV-1 LTR-driven PKR cDNA construct. Eur. J. Biochem. 264, 806-815.
20. MUTO, N.F., MARTINAND-MARI, C., ADELSON, M.E., and SUHADOLNIK, R.J. (1999). Inhibition of replication of reactivated human immunodeficiency virus type 1 (HIV-1) in latently infected U1 cells transduced with an HIV-1 long terminal repeat-driven PKR cDNA construct. J. Virol. 73, 9021-9028.
21. IACONO, K.T. (2002). Characterization of the human 2′,5′- oligoadenylate synthetase small isoform: inhibition of HIV-1 replication through intracellular immunization and delineation of the ATP binding domain. Ph.D. dissertation. Temple University, Philadelphia, Pennsylvania.
22. SOBOL, R.W., HENDERSON, E.E., KON, N., SHAO, J., HITZGES, P., MORDECHAI, E., CHARUBALA, R., SCHIRMEISTER, H., PFLEIDERER, W., and SUHADOLNIK, R.J. (1995). Inhibition of HIV-1 replication and activation of RNase L by phosphorothioate/phosphodiester 2′,5′-oligoadenylate derivatives. J. Biol. Chem. 270, 5963-5978.
23. CHARUBALA, R., PFLEIDERER, W., SUHADOLNIK, R.J., IACONO, K.T., MUTO, N.F., HOMAN, J.W., MARTINAND-MARI, C., HORVATH, S.E., HENDERSON, E.E., STEELE, A., and ROGERS, T.J. (2001). Inhibition of HIV-1 replication by chemically synthesized, nuclease-resistant, nontoxic (2′-5′)-oligoadenylate agonists. Nucleotides Helv. Chim. Acta 85, 2284-2299.
24. N6B. J. Acq. Immune Defic. Syndr. 30, 9-20.
25. KAUFMAN, R.J. (1999). Double-stranded RNA-activated protein kinase mediates virus-induced apoptosis: a new role for an old actor. Proc. Natl. Acad. Sci. USA 96, 11693-11695.
26. DER, S.D., YANG, Y.L., WEISSMANN, C., and WILLIAMS, B.R. (1997). A double-stranded RNA-activated protein kinase-dependent pathway mediating stress-induced apoptosis. Proc. Natl. Acad. Sci. USA 94, 3279-3283.
27. TAN, S.L., and KATZE, M.G. (1999). The emerging role of the interferon-induced PKR protein kinase as an apoptotic effector: a new face of death? J. Interferon Cytokine Res. 19, 543-554.
28. MEURS, E., CHANG, K., GALABRU, J., THOMAS, N.S., KERR, I.M., WILLIAMS, B.R.G., and HOVANESSIAN, A.G. (1990). Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell 62, 379-390.
29. CHU, W.M., OSTERTAG, D., LI, Z.W., CHANG, L., CHEN, Y., HU, Y., WILLIAMS, B., PERRAULT, J., and KARIN, M. (1999). JNK2 and IKKβ are required for activating the innate response to viral infection. Immunity 11, 721-731.
30. GIL, J., ALCAMI, J., and ESTEBAN, M. (1999). Induction of apoptosis by double-stranded RNA-dependent protein kinase (PKR) involves the α subunit of eukaryotic translation initiation factor 2 and NF-κB. Mol. Cell. Biol. 19, 4653-4663.
31. ROY, S., KATZE, M., PARKIN, N., EDERY, I., HOVANESS-IAN, A., and SONENBERG, N. (1990). Control of the interferon-induced 68-kilodalton protein kinase by the HIV-1 tat gene product. Science 247, 1216-1219.
32. TAN, S.-L., and KATZE, M.G. (2004). HSV.com: maneuvering the internetworks of viral neuropathogenesis and evasion of the host defense. Proc. Natl. Acad. Sci. USA 97, 5684-5686.
33. McMILLAN, N.A.J., CHUN, R.F., SIDEROVSKI, D.P., GALABRU, J., TOONE, W.M., SAMUEL, C.E., MAK, T., HOVANESSIAN, A.G., JEANG, K.-T., AND WILLIAMS, B.R.G. (1995). HIV-1 Tat directly interacts with the interferon-induced, double-stranded RNA-dependent kinase, PKR. Virology 213, 413-424.
34. CAI, R., CARPICK, B., CHUN, R.F., JEANG, K.T., and WILLIAMS, B.R.G. (2000). HIV-1 tat inhibits PKR activity by both RNA-dependent and RNA-independent mechanisms. Arch. Biochem. Biophys. 373, 361-367.
35. AKKINA, R., BANERJEA, A., BAI, J., ANDERSON, J., LI, M.J., and ROSSI, J. (2003). siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res. 23, 1997-2005.
36. GALIMI, F., and VERMA, I.M. (2002). Opportunities for the use of lentiviral vectors in human gene therapy. Curr. Top. Microbiol. Immunol. 261, 245-254.
37. MAUTINO, M.R., and MORGAN, R.A. (2002). Gene therapy of HIV-1 infection using lentiviral vectors expressing anti HIV-1 genes. AIDS Patient Care STDs 16, 11-26.
38. QIN, X.-F., AN, D.S., CHEN, I.S.Y., and BALTIMORE, D. (2003). Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 100, 183-188.
39. QUINONEZ, R., and SUTTON, R.E. (2002). Lentiviral vectors for gene delivery into cells. DNA Cell Biol. 21, 937-951.
40. RAMEZANI, A., HAWLEY, T.S., and HAWLEY, R.G. (2000). Lentiviral vectors for enhanced gene expression in human hematopoietic cells. Mol. Ther. 2, 458-469.
41. SUTTON, R.E., WU, H.T.M., RIGG, R., BOHNLEIN, E., and BROWN, P.O. (1998). Human immunodeficiency virus type 1 vectors efficiently transduce human hematopoietic stem cells. J. Virol. 72, 5781-5788.
42. (+) cord blood cells after ex vivo expansion: evidence for the amplification and self-renewal of repopulating stem cells. Blood 93, 3736-3749.
43. + human cord blood cells. Blood 94, 3644-3652.
44. KHABAR, K.S.A., SIDDIQUI, Y.M., AL-ZOGHAIBI, F., ALHAJ, L., DHALLA, M., ZHOU, A., DONG, B., WHITMORE, M., PARANJAPE, J., AL-AHDAL, M.N., AL-MOHANNA, F., WILLIAMS, B.R.G., and SILVERMAN, R.H. (2003). RNase L mediates transient control of the interferon response through modulation of the double-stranded RNA-dependent protein kinase PKR. J. Biol. Chem. 278, 20124-20132.
45. + hematopoietic progenitor cells with an antitat gene protects T-cell and macrophage progeny from AIDS virus infection. J. Virol. 71, 2740-2746.
46. FEHSE, B., KUSTIKOVA, O.S., BUBENHEIM, M., and BAUM, C. (2004). Pois(s)on - it's a question of dose. Gene Ther. 11, 879-881.
47. KUSTIKOVA, O.S., WAHLERS, A., KUHLCKE, K., STAHLE, B., ZANDER, A.R., BAUM, C., and FEHSE, B. (2003). Dose finding with retroviral vectors: correlation of retroviral vector copy numbers in single cells with gene transfer efficiency in a cell population. Blood 102, 3934-3937.
48. + hematopoietic stem/progenitor cells from human umbilical cord blood. J. Exp. Med. 178, 2089-2096.
49. SCHRÖDER, H.C., WENGER, R., KUCHINO, Y., and MÜLLER, W.E.G. (1989) Modulation of nuclear matrix-associated 2′,5′-oligoadenylate metabolism and ribonuclease L activity in H9 cells by human immunodeficiency virus. J. Biol. Chem. 264, 5669-5673.
50. JUDEWARE, R., LI, J., and PETRYSHYN, R. (1993). Inhibition of the dsRNA-dependent protein kinase by a peptide derived from the human immunodeficiency virus type 1 tat protein. J. Interferon Res. 13, 153-160.
51. BOSINGER, S.E., HOSIAWA, K.A., CAMERON, M.J., PERSAD, D., RAN, L., XU, L., BOULASSEL, M.R., PARENTEAU, M., FOURNIER, J., RUD, E.W., and KELVIN, D.J. (2004). Gene expression profiling of host response in models of acute HIV infection. J. Immunol. 173, 6858-6863.
52. DAS, D., WARD, S.V., MARKLE, D., and SAMUEL, C.E. (2004). DNA damage-binding proteins and heterogeneous nuclear ribonucleoprotein A1 function and constitutive KCS element components of the interferon-inducible RNA-dependent protein kinase promoter. J. Biol. Chem. 279, 7313-7321.
53. PACCHIA, A.L., ADELSON, M.E., KAUL, M., RON, Y., and DOUGHERTY, J.P. (2001). An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. Virology 282, 77-86.
54. CHINNASAMY, N., CHINNASAMY, D., TOSO, J.F., LAPOINTE, R., CANDOTTI, F., MORGAN, R.A., and HWU, P. (2000). Efficient gene transfer to human peripheral blood monocyte-derived dendritic cells using human immunodeficiency virus type 1-based lentiviral vectors. Hum. Gene Ther. 11, 1901-1909.
55. REISER, J., LAI, Z., ZHANG, X.-Y., and BRADY, R.O. (2000). Development of multigene and regulated lentivirus vectors. J. Viral. 74, 10589-10599.
56. MACGREGOR, R.R. (2001). Clinical protocol: a phase 1 open label clinical trial of the safety and tolerability of single escalating doses of autologous CD4 T cells transduced with VRX496 in HIV-positive subjects. Hum. Gene Ther. 12, 2028-2029.
57. HUMEAU, L.M., BINDER, G.K., LU, X., SLEPUSHKIN, V., MERLING, R., ECHEAGARAY, P., PEREIRA, M., SLEPUSHKINA, T., BARNETT, S., DROPULIC, L.K., CARROLL, R., LEVINE, B.L., JUNE, C.H., and DROPULIC, B. (2004). Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol. Ther. 9, 902-913.
58. AN, D.S., MORIZONO, K., LI, Q.-X., MAO, S.H., LU, S., and CHEN, I.S.Y. (1999). An inducible human immunodeficiency virus type 1 (HIV-1) vector which effectively suppresses HIV-1 replication. J. Virol. 73, 7671-7677.
59. BUKOVSKY, A.A., SONG, J.P., and NALDINI, L. (1999). Interaction of human immunodeficiency virus-derived vectors with wild-type virus in transduced cells. J. Virol. 73, 7087-7092.
60. CORBEAU, P., and WONG-STAAL, F. (1998). Anti-HIV effects of HIV vectors. Virology 243, 268-274.
61. KLIMATCHEVA, E., PLANELLES, V., DAY, S.L., FULREADER, F., RENDA, M.J., and ROSENBLATT, J. (2001). Defective lentiviral vectors are efficiently trafficked by HIV-1 and inhibit its replication. Mol. Ther. 3, 928-939.
62. MAUTINO, M.R., and MORGAN, R.A. (2002). Enhanced inhibition of human immunodeficiency virus type 1 replication by novel lentiviral vectors expressing human immunodeficiency virus type 1 envelope antisense RNA. Hum. Gene Ther. 13, 1027-1037.
63. MAUTINO, M.R., and MORGAN, R.A. (2002). Inhibition of HIV-1 replication by novel lentiviral vectors expressing transdominant Rev and HIV-1 env antisense. Gene Ther. 9, 421-431.
64. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70, 2581-2585.
65. AN, D.S., KOYANAGI, Y., ZHAO, J.-Q., AKKINA, R., BRISTOL, G., YAMAMOTO, N., ZACK, J.A., and CHEN, I.S.Y. (1997). High-efficiency transduction of human lymphoid progenitor cells and expression in differentiated T cells. J. Virol. 71, 1397-1404.
66. YU, M., LEAVITT, M.C., MARUYAMA, M., YAMADA, O., YOUNG, D., HO, A.D., and WONG-STAAL, F. (1995). Intracellular immunization of human fetal cord blood stem/progenitor cells with a ribozyme against human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. USA 92, 699-703.
67. + cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 89, 2259-2267.
68. VATTEM, K.M., STASCHKE, K.A., ZHU, S., and WEK, R.C. (2001). Inhibitory sequences in the N-terminus of the double-stranded RNA-dependent protein kinase, PKR, are important for regulating phosphorylation of eukaryotic initiation factor 2α (eIF2α). Eur. J. Biochem. 268, 1143-1153.
69. JIANG, H.-Y., WEK, S.A., McGRATH, B.C., LU, D., HAI, T., HARDING, H.P., WANG, X., RON, D., CAVENER, D.R., and WEK, R.C. (2004). Activating transcription factor 3 is integral to the eukaryotic initiation factor 2 kinase stress response. Mol. Cell. Biol. 24, 1365-1377.
70. WU, S., and KAUFMAN, R.J. (1997). A model for the double-stranded RNA (dsRNA)-dependent dimerization and activation of the dsRNA-activated protein kinase PKR. J. Biol. Chem. 272, 1291-1296.
71. WILLIAMS, B.R.G. (2001). Signal integration via PKR. Sci STKE Jul 3;(89):RE2.
72. WU, J.M., CHIAO, J.W., and MAAYAN, S. (1986). Diagnostic value of the determination of an interferon-induced enzyme activity: decreased 2′,5′-oligoadenylate-dependent binding protein activity in AIDS patient lymphocytes. AIDS Res. 2, 127-133.
73. MARTINAND, C., MONTAVON, C., SALEHZADA, T., SILHOL, M., LEBLEU, B., and BISBAL, C. (1999). RNase L inhibitor is induced during human immunodeficiency virus type 1 infection and downregulates the 2-5A/RNase L pathway in human T cells. J. Virol. 73, 290-296.
74. MAUTINO, M. R., KEISER, N., and MORGAN, R. A. (2001). Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant rev. J. Virol. 75, 3590-3599.
75. MESNIL, M., and YAMASKAI, H. (2000). Bystander effect in herpes simplex virus-thymidine kinase/ganciclovir cancer gene therapy: role of gap-junctional intercellular communication. Cancer Res. 60, 3989-3999.